Welcome to our dedicated page for America Great Health SEC filings (Ticker: AAGH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
America Great Health filings document public-company governance and executive-officer changes for the Wyoming registrant. Its Form 8-K disclosures center on Item 5.02 matters, including the departure of a principal financial officer and interim assignment of chief financial officer, principal financial officer, and principal accounting officer responsibilities. The filing record also identifies the company as an Exchange Act reporting issuer and records formal board and signature actions tied to material events.
America Great Health (AAGH) reports interim results from a small, observational clinical study of its ion‑modified peptide products AX-3 and PPY-3 used as adjunctive therapy. The study at Zhejiang Kangjing Hospital in China followed 10 subjects from December 2024 through May 2026, including 8 with solid tumors, 1 with malignant lymphoma and 1 with bronchiectasis with hemoptysis.
The report describes symptom improvements in some patients and detailed changes in vital signs, blood counts, lipids and immune-cell markers. Two subjects with advanced malignancies and multiple-organ failure died within approximately one month and were withdrawn. The hospital concluded there were no significant treatment-related toxicities or adverse effects aside from discomfort swallowing large capsules. America Great Health emphasizes that this was a non-randomized, uncontrolled, preliminary observation, that concurrent therapies confound interpretation, and that the results do not establish safety or efficacy; further controlled clinical studies would be required.
America Great Health reported very small operations and a highly leveraged balance sheet for the quarter and nine months ended March 31, 2026. Sales were $26,143 for the quarter and $258,802 for the nine months, generating nine‑month gross profit of $171,748.
The company recorded nine‑month net income of $861,105, versus a prior‑year loss, but management explains this was mainly driven by a non‑recurring $1,395,000 gain from extinguishment of aged accounts payable in the prior quarter, not by ongoing operations, which remained loss‑making in the latest quarter.
The balance sheet shows total assets of $167,105 against total liabilities of $5,047,740, resulting in a shareholders’ deficit of $4,880,635 and negative working capital of about $2.48 million. Cash was only $29,346, and the company relies on short‑term loans and $1,254,114 of advances from its majority shareholder, plus $2,423,349 of long‑term loans bearing interest mostly around 20%. Management states that recurring losses, limited cash, and the large deficit create substantial doubt about the company’s ability to continue as a going concern and plans to fund operations through additional capital and shareholder support.
Revenue is concentrated, with 71–76% from Asia and significant dependence on a handful of customers and suppliers. Management also notes prior auditor disclaimer of opinion on earlier annual financials and concludes that disclosure controls and procedures remain not effective due to material weaknesses including lack of an audit committee, independent directors, and sufficient accounting staff.
America Great Health reported sales of $232,659 for the six months ended December 31, 2025, roughly flat year over year, but gross profit fell to $149,215 as wholesale mix raised cost of goods sold.
The company posted net income of $1,027,321, driven mainly by a one‑time $1,395,000 gain from extinguishment of aged accounts payable, while operations still generated an operating loss of $202,159. Cash was only $22,904 with negative working capital of $2,404,215 and shareholders’ deficit of $4,715,116.
Management highlights substantial doubt about the ability to continue as a going concern, citing recurring losses historically, heavy short‑ and long‑term high‑interest loans, and dependence on advances from the majority shareholder.
America Great Health reported quarterly sales of $187,559 for the three months ended September 30, 2025, up from $140,126 a year earlier, but still posted a net loss of $85,363.
Gross profit was $112,679, while operating expenses fell to $116,063, narrowing the loss versus the prior-year period. Cash was only $28,079 with total liabilities of $6,070,405 and a shareholders’ deficit of $5,829,109, leading management to state there is substantial doubt about the company’s ability to continue as a going concern.
The company relies on high-interest short- and long-term loans, including $1,323,138 in long-term debt at rates up to 20%, and advances from its majority shareholder to fund operations.
America Great Health reported modest growth but remains deeply unprofitable and financially stressed for the year ended June 30, 2025. Sales rose to $391,743 from $294,670 and gross profit doubled to $339,121, helped by lower cost of goods sold.
Operating expenses were $722,056, leading to a net loss of $721,242, narrower than the $1,226,362 loss a year earlier. Cash was only $44,056, with a working capital deficit of $3,584,235 and total shareholders’ deficit of $5,743,827, creating substantial doubt about the company’s ability to continue as a going concern.
The auditor issued a disclaimer of opinion on the 2025 and 2024 financial statements due to insufficient audit evidence over expenses, opening balances and the Purecell Group consolidation analysis. The company also reported material weaknesses in internal control, relies heavily on loans and advances from its majority shareholder, and its thinly traded OTC penny stock faces limited liquidity.
America Great Health reported that its Chief Financial Officer, Quinn Chen, submitted his resignation, which the company accepted on June 2, 2025, to be effective June 30, 2025. The company states that Mr. Chen is leaving for personal reasons and that there were no disagreements with the company, including no issues related to its operations, policies, or accounting practices.
The Board plans to search for internal and external candidates to fill the CFO role. Until a successor is appointed, President and Chief Executive Officer Mike Wang will also serve as Chief Financial Officer, acting as the company’s principal financial and principal accounting officer.